Mantle Cell Lymphoma, An Issue of Hematology/Oncology Clinics of North America, Volume 34-5 (Hardcover)


This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

R2,237

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles22370
Mobicred@R210pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 12 - 17 working days


Toggle WishListAdd to wish list
Review this Item

Product Description

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Elsevier - Health Sciences Division

Country of origin

United States

Series

The Clinics: Internal Medicine

Release date

September 2020

Availability

Expected to ship within 12 - 17 working days

First published

2020

Editors

Dimensions

160 x 237 x 17mm (L x W x T)

Format

Hardcover

Pages

240

ISBN-13

978-0-323-76312-7

Barcode

9780323763127

Categories

LSN

0-323-76312-X



Trending On Loot